Novo Nordisk (NVO), the maker of the popular diabetes and weight-loss drugs Ozempic and Wegovy, expects at least some ...

After screening 20,000 protein-encoding genes in the human body, Stanford researchers have identified a naturally occurring ...

In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...

A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide—also known as ...

As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

U.S. taxpayers spent billions developing Ozempic-type diabetes and weight-loss drugs — now those drugs’ markups could ...

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight ...